Information Provided By:
Fly News Breaks for December 30, 2016
GALE
Dec 30, 2016 | 08:09 EDT
Maxim analyst Jason McCarthy said having a confirmed regulatory path from the FDA for GALE-401 for the treatment essential thrombocythemia is a significant positive for Galena. Noting that more study details are expected in early 2017, McCarthy keeps a Buy rating and $4 price target on Galena shares.
News For GALE From the Last 2 Days
There are no results for your query GALE